Basilea Pharmaceutica Ltd. Logo
 

News

 
 
Language
Year
Keyword
 
Monday, August 15. 2016
 
  • Antifungal CRESEMBA® (isavuconazole) launched in first European markets
  • Entered contract with BARDA for the development and potential US registration of the antibiotic ceftobiprole (European trade name Zevtera® or Mabelio®)
  • Half-year cash and financial investments of CHF 311 million
 
more...
 
Monday, June 27. 2016
 
Basel, Switzerland, June 27, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announces that it has launched its new azole antifungal CRESEMBA® (isavuconazole) in Italy and will sponsor today a continuing medical education event on current challenges and recent developments in the management of invasive fungal infections in Bologna, Italy. The event will be co-chaired by Prof. Claudio Viscoli MD, Professor of Infectious Diseases, University of Genova and Prof. Corrado Girmenia MD, Professor of Haematology, Sapienza University of Rome.
 
more...
 
Thursday, June 09. 2016
 
  • Clinical data reported from completed phase 1/2a study of BAL101553, with once-weekly 2-hour infusion showing signals of clinical activity
  • Design of ongoing phase 1/2a study with once-daily oral BAL101553 presented, with four dose cohorts completed
  • Design of ongoing BAL3833 oral phase 1 study presented, with four dose cohorts completed
 
more...
 
Thursday, April 21. 2016
 
Basel, Switzerland, April 21, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported that the shareholders approved all agenda items proposed by the Board of Directors at today's Ordinary General Meeting of Shareholders (AGM) for the financial year 2015. At the meeting, 33.2 percent of Basilea's share capital was represented.
 
more...
 
Thursday, April 21. 2016
 
  • Tumor checkpoint controller BAL101553 demonstrates pre-clinical activity in treatment-refractory glioblastoma models as single agent and in combination treatment
  • PanRAF/SRC kinase inhibitor BAL3833 inhibits tumor growth in preclinical KRAS-driven cancer models
 
more...
 
Wednesday, April 20. 2016
 
Basel, Switzerland, April 20, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the Biomedical Advanced Research and Development Authority (BARDA), a division within the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, has entered into a contract with Basilea Pharmaceutica International Ltd. ("Basilea") for the clinical phase 3 development aiming at regulatory approval of Basilea's broad-spectrum antibiotic ceftobiprole in the United States.
 
more...
 
Friday, April 15. 2016
 
  • Post-hoc analysis on clinical response of ceftobiprole in staphylococcal bacteremia
 
more...
 
Tuesday, March 15. 2016
 
  • Dr. Martin Nicklasson has determined not to stand for re-election as Chairman but will stand for re-election as Member of the Board
  • Domenico Scala nominated as new Chairman of the Board
 
more...
 
Wednesday, March 09. 2016
 
Basel, Switzerland, March 09, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that results from the open-label phase 3 VITAL study evaluating CRESEMBA® (isavuconazole) in adult patients with mucormycosis were published in The Lancet Infectious Diseases. The article, titled "Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis", was published online on March 8 and will also appear in a future print issue of the journal.1
 
more...
 
Friday, March 04. 2016
 
Basel, Switzerland, March 04, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) hosts a symposium to support the launch of the new azole antifungal CRESEMBA® (isavuconazole) in Germany. The symposium will be held on March 5 and 6, 2016 in Berlin. The symposium is co-chaired by Prof. Oliver A. Cornely, Department of Internal Medicine I, University of Cologne, Germany; and Prof. Andrew J. Ullmann, Julius-Maximilians-University, Department of Internal Medicine II, Infectious Diseases, Würzburg, Germany. The focus of the symposium will be on current challenges and recent developments in the management of invasive mold infections.
 
more...
 
more back
Info